Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 522

1.

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group.

Am J Geriatr Psychiatry. 2006 May;14(5):428-37.

PMID:
16670247
2.

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

Feldman HH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):263-8.

PMID:
17132971
3.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
4.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
5.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group.

JAMA. 2004 Jan 21;291(3):317-24.

PMID:
14734594
6.

Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.

Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.

Dement Geriatr Cogn Disord. 2008;26(5):458-66. doi: 10.1159/000167267. Epub 2008 Nov 4.

PMID:
18984956
7.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
8.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group.

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
9.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group.

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
10.
11.

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

Wilkinson D, Andersen HF.

Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.

PMID:
17622761
12.

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.

Schmitt FA, van Dyck CH, Wichems CH, Olin JT; Memantine MEM-MD-02 Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):255-62.

PMID:
17132970
13.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
14.

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.

Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15.

PMID:
16861375
15.

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.

Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S.

Alzheimers Dement. 2009 Sep;5(5):369-74. doi: 10.1016/j.jalz.2009.05.604.

PMID:
19751915
16.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
17.

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.

Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P; Donepezil MSAD Study Investigators Group.

J Am Geriatr Soc. 2003 Jun;51(6):737-44. Erratum in: J Am Geriatr Soc. 2003 Sep;51(9):1331.

PMID:
12757558
18.

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.

Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P.

Int J Geriatr Psychiatry. 2008 Sep;23(9):979-81. doi: 10.1002/gps.1979. No abstract available.

PMID:
18229874
19.

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; Memantine MEM-MD-01 Study Group.

Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):136-43.

PMID:
17545739
20.

Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.

Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.

Curr Med Res Opin. 2007 Dec;23(12):3153-65.

PMID:
17988434

Supplemental Content

Support Center